Corcept Therapeutics Incorporated Share Price & Technical Analysis
CORT · $60.22 (+0.89%)
Healthcare / Biotechnology
$60.22
+0.89%
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
24% return in May, 15% avg return in past 3 year May month.
56% return in 2026, 65% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 11% | -11% | 16% | 15% | 24% | – | – | – | – | – | – | – | 56% |
| 25 | 32% | -7% | 86% | -37% | 9% | -5% | -8% | 8% | 20% | -12% | 9% | -55% | 38% |
| 24 | -5% | 10% | 7% | -7% | 31% | 8% | 19% | -8% | 32% | 5% | 19% | -12% | 99% |
| 23 | 12% | -9% | 5% | 2% | 5% | -6% | 15% | 28% | -17% | 3% | -9% | 27% | 58% |
| 22 | -5% | 18% | 0% | -6% | -4% | 13% | 20% | -8% | 0% | 12% | -12% | -20% | 10% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.45B
P/E ratio
145.17
52W high
$91.00
52W low
$28.66
Volume
5,36,007
Beta
0.35
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Corcept Therapeutics Incorporated share price today?
- Corcept Therapeutics Incorporated (CORT) last traded around $60.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CORT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CORT. Download the app for real-time alerts.
- How can I analyze Corcept Therapeutics Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.